A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Purpose
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Condition
- Migraine
Eligibility
- Eligible Ages
- Between 6 Years and 17 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria: - History of migraine attacks for more than 6 months - Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit - Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours - Participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator - Participant must be able to swallow a tablet - For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening - Participants must weigh at least 15 kilograms (kg)
Exclusion Criteria
- Participants must not be pregnant or nursing - Participants must not have any acute, serious, or unstable medical condition - Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Lasmiditan High Dose |
Lasmiditan administered orally with matching placebo to maintain the blind. |
|
Experimental Lasmiditan Mid Dose |
Lasmiditan administered orally with matching placebo to maintain the blind. |
|
Experimental Lasmiditan Low Dose |
Lasmiditan administered orally with matching placebo to maintain the blind. |
|
Placebo Comparator Placebo |
Placebo administered orally. |
|
Recruiting Locations
Children's National and nearby locations
Children's National Medical Center
Washington, District of Columbia 20010
Washington, District of Columbia 20010
More Details
- NCT ID
- NCT04396236
- Status
- Recruiting
- Sponsor
- Eli Lilly and Company
Study Contact
There will be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or1-317-615-4559
ClinicalTrials.gov@lilly.com